Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund ...

Biotech ETFs offer diversified exposure to the sector, reducing investment risk. Investing in top biotech ETFs can be cost-effective due to their low expense ratios. Large biotech ETFs provide better ...

Fri, April 3, 2026 at 2:17 PM UTC The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion ...

Sun, December 14, 2025 at 4:58 PM UTC As the AI trade gets overheated and calls for some sort of bursting of the AI bubble grow louder, it might make sense to look to opportunities to be had within ...

State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Biotech ETF BBC hits a 52-week high, likely fueled by strong clinical trial results and rising M&A activity, and renewed risk-on sentiment.

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

The best health care ETFs offer diversification across medical industries as well as exposure to a sector with lower volatility than the broader market.

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...